Minoryx and Palobiofarma were the two companies awarded with the Premi Bioèxit award – Biosuccess of the Year – which is given annually at the event by CataloniaBio. Minoryx, committed to finding innovative treatments for life threatening rare diseases, received the award for their recent success in leveraging a €19m finance round with international investors; Palobiofarma, created in 2006 to discover new drugs based on the modulation of adenosine receptors, were winners for licensing a promising drug against cancer to Novartis.
